Fujii Takashi, Takeuchi Satoru, Toyooka Terushige, Otani Naoki, Wada Kojiro, Mori Kentaro
Department of Neurosurgery, National Defense Medical College.
No Shinkei Geka. 2018 Nov;46(11):975-982. doi: 10.11477/mf.1436203851.
Papillary thyroid carcinoma is the most common thyroid malignancy and usually has an indolent clinical course with a good prognosis. Brain metastasis from thyroid cancer is very rare, occurring in only 0.8-1.3% of all papillary thyroid carcinomas; therefore, the prognosis and treatment of the metastatic tumor are unclear. We describe 5 cases of brain metastases from papillary thyroid carcinoma treated with surgery between 2013 and 2017. Intracranial tumor resection was performed and brain metastases were pathologically diagnosed as papillary thyroid carcinoma in 2 men and 3 women aged 62-72 years(mean 67 years). The surgical treatment for the thyroid cancer was total thyroidectomy in 3 patients, hemithyroidectomy in 1, and no treatment in 1. The duration from initial diagnosis to brain metastasis was 0-155 months(mean 73.2 months). Two patients also received radioiodine therapy. Three patients had multiple lesions and 2 had single lesions. Four patients also had other metastases. Neuroimaging demonstrated intratumoral hemorrhages in 2 patients. The other 2 patients had intratumoral hemorrhage during the course of the disease. All patients received radiation therapy after surgery for brain metastases. Two patients died, but the other 3 have survived to date. The other 2 patients who had intratumoral hemorrhage during the course of the disease received I radioiodine therapy. It was reported that I radioiodine therapy resulted in collapse of the fragile peritumoral vessels. It is safe to perform head magnetic resonance imaging(MRI)before radioiodine therapy for thyroid cancer. Papillary thyroid carcinomas carry a good prognosis but some brain metastases have a poor prognosis due to the presence of other metastases or the patient's poor general condition. Treatments for patients in good general condition are needed to improve the clinical course and prognosis.
甲状腺乳头状癌是最常见的甲状腺恶性肿瘤,通常临床病程进展缓慢,预后良好。甲状腺癌脑转移非常罕见,仅占所有甲状腺乳头状癌的0.8 - 1.3%;因此,转移性肿瘤的预后和治疗尚不清楚。我们描述了2013年至2017年间接受手术治疗的5例甲状腺乳头状癌脑转移病例。对62 - 72岁(平均67岁)的2名男性和3名女性进行了颅内肿瘤切除术,脑转移灶经病理诊断为甲状腺乳头状癌。3例患者的甲状腺癌手术治疗为全甲状腺切除术,1例为甲状腺次全切除术,1例未接受治疗。从初次诊断到发生脑转移的时间为0 - 155个月(平均73.2个月)。2例患者还接受了放射性碘治疗。3例患者有多个病灶,2例有单个病灶。4例患者还伴有其他转移灶。神经影像学检查显示2例患者肿瘤内出血。另外2例患者在疾病过程中出现肿瘤内出血。所有患者术后均接受了脑转移灶的放射治疗。2例患者死亡,但另外3例至今存活。在疾病过程中出现肿瘤内出血的另外2例患者接受了放射性碘治疗。据报道,放射性碘治疗导致肿瘤周围脆弱血管破裂。在甲状腺癌放射性碘治疗前进行头部磁共振成像(MRI)是安全的。甲状腺乳头状癌预后良好,但一些脑转移患者由于存在其他转移灶或患者一般状况较差,预后不良。需要对一般状况良好的患者进行治疗,以改善临床病程和预后。